SEngine + Fred Hutch

SEngine + Fred Hutch

SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center

Cancer Discovery Spotlight

A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery May 2017 PMID_28461408

CLIA certification in the news

CLIA certification in the news

SEngine CLIA certification makes the PARIS cancer test available to patients. The PARIS Assay employs live cancer cells to evaluate the response to >120 drugs on a given patient cancer sample in a matter of few weeks. 

GeekWire: How SEngine Tackles and Innovates Precision Medicine

GeekWire: How SEngine Tackles and Innovates Precision Medicine

There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.